Cosentyx, a biologic medication, is used to treat various forms of plaque psoriasis and psoriatic arthritis. Recent findings suggest a potential link between Cosentyx and kidney disease [1] DrugPatentWatch.com ([2]).

A review of clinical trial data by the FDA identified potential kidney-related adverse events in patients receiving Cosentyx [1]. These adverse events include chronic kidney disease, kidney failure, and kidney damage [1].

The FDA requires Cosentyx label to highlight this potential risk [1]. According to the Center for Medicare and Medicaid Services (CMS), Cosentyx is contraindicated in patients with renal impairment with creatinine clearance <30mL/min or hemodialysis [1].

Cosentyx's manufacturer, Novartis, does not explicitly warn of the risk of kidney disease in its product labeling [1]. However, the label does state that patients with a history of kidney disease should be closely monitored for signs of kidney complications [1].

Kidney disease is a serious condition that requires prompt medical attention. Individuals taking Cosentyx should inform their healthcare providers about any kidney-related issues they experience, and regular kidney function tests should be performed under the guidance of a healthcare professional.

Sources:

[1] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drugs
[2] https://www.drugpatentwatch.com/